Clinical trials recruiting for Melanoma Stage IV
23
Recruiting trials
21
US states with sites
12
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 6 |
| Florida | 6 |
| New York | 3 |
| Pennsylvania | 3 |
| Indiana | 2 |
| Kentucky | 2 |
| Nebraska | 2 |
| Ohio | 2 |
| Tennessee | 2 |
| Texas | 2 |
| Wisconsin | 2 |
| Arizona | 1 |
Top cities
Los Angeles, California 3New York, New York 3Orange, California 3Pittsburgh, Pennsylvania 3Tampa, Florida 3Houston, Texas 2Indianapolis, Indiana 2Madison, Wisconsin 2Miami, Florida 2Nashville, Tennessee 2
Self-screener
Recruiting trials
- A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
- A Study of VET3-TGI in Patients With Solid Tumors
- Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
- Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
- Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
- Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma
- Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
- Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
- Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
- Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients
- Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain
- FMT to Convert Response to Immunotherapy
- IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
- Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
- MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
- Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
- Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
- Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial
- Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
- Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
- To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma
- Urinary Microbiome as a Biomarker for Melanoma Diagnosis and Response Prediction to Systemic Tumour Therapy
- Versatile Ampification Single-Molecule Detection in Liquid Biopsy
Related conditions
Trials recruiting for Melanoma Stage IV often also study these conditions. Each links to its own recruiting-trial list.
Melanoma 487Melanoma Stage III 18Non-small cell lung cancer 507Melanoma (Skin) 18Lung cancer 2180Cutaneous Melanoma 27Unresectable Melanoma 11Triple-negative breast cancer 138Squamous Cell Carcinoma 14Solid Tumor, Adult 38
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Melanoma Stage IV trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.